• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·300791.SZ
Share

Sirio Pharma Co., Ltd. Stocks

CN¥ 18.16Last Updated 09.10.2026

Issuer Rating

3/7
Performance

Average

Risk

High

Recommendation

Sell

Market Cap

CN¥ 847.68M

CN¥ 18.16
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Weak growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1993 and headquartered in Shantou, China, Sirio Pharma Co., Ltd. serves as a global contract manufacturer. The company is dedicated to producing a broad spectrum of dietary supplements, encompassing traditional and vegetarian softgels, a wide range of nutraceutical gummies, probiotic formulations, tablets, powders, capsules, and functional beverages. Beyond manufacturing, Sirio Pharma also offers complete primary and final packaging solutions to its customers.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, neutral on E

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of 300791.SZ is 23.0 and suggests 23.7% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 00:49

What do analysts think about Trump's announced Russia-Ukraine energy ceasefire?

11.10.2026 21:01

IPO roundup: Firmus collapse sends AI funding warning; DeepSeek seeking $12 bln

11.10.2026 09:19

Twelve killed in attack on Riyadh airport

10.10.2026 16:01

Small caps last week: Webull risks, Levi’s outlook, Vaxcyte trial success

10.10.2026 13:01

How soon will the AI bubble burst? Will France infect the Eurozone? What's wrong with Levi's jeans?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026